Regeneron Pharmaceuticals Investor update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, and welcome to Regeneron's conference call to discuss Regeneron's Genetic Center and MASH siRNA development programs. My name is Kevin, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations.
You may begin. Thank you, Kevin.
Good morning, and welcome to our Regeneron Roundtable Investor Event, a series of presentations spotlighting key opportunities across Regeneron's pipeline. Today's dual-purpose roundtable will highlight Regeneron's leading genetic efforts through the Regeneron Genetics Center, or RGC, and our MASH siRNA development programs, which are informed by valuable human genetic insights from the RGC. Before we begin, I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Let's begin. Today's roundtable will highlight the differentiated capabilities of the Regeneron Genetics Center and our MASH siRNA portfolio, led by the CIDEB siRNA program, which is rapidly advancing into registrational studies.
Today's speaker panel brings together leaders spanning research, clinical development, and commercial strategy. First, Dr. George Yancopoulos, Regeneron's Co-Founder, Board Co-Chair, President, and Chief Scientific Officer, will provide a quick overview of our RGC efforts and the MASH pipeline. Next, Dr. Aris Baras, Senior Vice President, Head of Regeneron Genetics Center, Co-Head of Regeneron Genetic Medicines, will provide a broad overview of our Regeneron Genetics Center efforts and how it informs nearly everything we do at Regeneron. Then, Dr. Gary Herman, Senior Vice President, Clinical Development Unit Head, Regeneron Genetic Medicines, will discuss our portfolio of MASH siRNAs, including the recently presented data for our CIDEB siRNA program.
Finally, Josh Adelson, Executive Director, Commercial, New Products, will touch upon our market analysis of MASH and how our CIDEB siRNA has the potential to be paradigm-shifting upon clinical validation. We will then use the remaining time for Q&A. With that, let me now turn the call over to George.
Thanks, Ryan. At Regeneron, we have always focused on genetics to address a major bottleneck in our business, the lack of great targets for diseases where better medicines are still needed. At Regeneron, we have always prioritized genetics, both mouse and human. Rather than rely on the literature and discoveries of the rest of the world, we chose to build on our initial mouse genetics capability and then decided to invest deeply to create our own human genetics discovery engine that we call the Regeneron Genetics Center, or the RGC, to fuel the next wave of Regeneron targets and therapeutics. Today, you'll hear a little bit about the RGC and what it can deliver.
Almost 15 years later, we have the largest multiomics database that we are aware of, nearly 4 million individuals with multiomics data, including DNA sequences and proteomics, linked to de-identified longitudinal health records and other rich human health data. That includes about 3.3 million individuals with data generated internally and about 700,000 from in-licensing. Add to that over a decade of proprietary data curation, advanced analytics, and AI, and we have discovered and validated nearly 50 new targets across our pipeline. The impact of the RGC goes far beyond target discovery. We also use human genetics to guide development across as much of the pipeline as possible, from selecting additional indications, as we did to help guide DUPIXENT to nine FDA-approved indications, to identifying response biomarkers and informing clinical trial design and enrollment. CIDEB shows the full arc.
We discovered the target several years ago and achieved clinical proof of concept in 2026. Lastly, over the last five years plus, the RGC has expanded from human genetics into proteomics, developing risk scores and biomarkers for disease, clinical outcomes, and health traits that have been instrumental in our clinical trials. They also show potential to diagnose and predict disease progression better than existing standards, and ultimately to offer a single test to evaluate risk across dozens and dozens of diseases. Combining our multiomics database and approaches could reimagine healthcare management with greater efficiency, lower costs, and better outcomes for patients, providers, and payers. In short, we are using multiomics both to discover new drug targets and to revolutionize healthcare. Next slide, please. One of Regeneron's early and sustained differentiating approaches has been to focus on large-effect genetics.
These include variants that can cause genetic diseases, such as CAPS or the otoferlin forms of congenital hearing loss, as well as protective variants, such as PCSK9 in heart disease and CIDEB in liver disease, along with dozens of additional protective variants that the RGC has identified across all of our therapeutic areas. We look for what I call superhumans from nature's experiment, people at the genetic extremes, especially those protected from a disease that harms everyone else. On the curve on the left, most people sit in the middle. The most useful discoveries are at the ends. A protective variant tells us which gene to turn down and what benefit could look like in a person. To find them, we combine three approaches. First, large-scale sequencing and proteomics to find the rare variants. To date, we have access to nearly 4 million sequenced individuals across our collaborations and studies.
Second, linked electronic health records, because DNA alone is just a code. Tied to years of sample imaging and diagnosis, these health records show what a genetic variant does. Third, AI to analyze all of it at scale. The result: approximately 50 potential novel targets so far across the organ systems on the right, from metabolism and cardiovascular and neuroscience and ophthalmology. Targets backed by rare protective variants like these are about six times more likely to be approved than targets with no genetic support. More programs in a pipeline were either discovered by human genetics, like CIDEB, or supported by it, like DUPIXENT. Let me show you what one of these 50 targets looks like today, on the next slide.
We are highlighting today one of our most recent and exciting stories, a target discovered here at Regeneron by the Regeneron Genetics Center, where we now have a therapeutic candidate in the clinic with encouraging results. Less than five years ago, the RGC discovered a new protective variant in MASH. On the left, in our analysis of millions of individuals, we found there are rare individuals, approximately one in 500, who carry a loss-of-function variant in CIDEB, have lower serum ALT, a marker of liver injury, less liver fat, and a 43% lower risk of liver disease. That is nature's experiment. The question: Can a medicine do to a patient what the variant does on a population level? Through our collaboration with Alnylam, we developed an siRNA targeting CIDEB and moved quickly into the clinic. Just a few days ago, we simultaneously presented and published the results.
On the right, you can see that single doses produced rapid, deep, and long-lasting normalization of liver fat in patients with liver disease, with reductions of up to 80% from baseline across tested doses, lasting for many months. Gary Herman will expand on these results in detail shortly. This is a full-circle moment, from a human genetic discovery to clinical proof of concept in patients. The clinical benefit we observe with CIDEB siRNA validates our genetics-driven approach and supports CIDEB as a potential medicine for the growing MASH patient population. MASH is dramatically underdiagnosed and undertreated today, and we expect that to change as treatment options and diagnosis rates increase. Now, I'll hand it over to Aris Baras to show you how the Regeneron Genetics Center delivers this again and again, and how it guides development decisions, and with AI and multiomics, supports new diagnostic opportunities as well.
Thanks, George. Moving to slide eight. We have long believed and seen in our own experience that human genetics evidence improves the probability of drug development success. Recently, we have been able to put some numbers behind that. According to an analysis of databases tracking drug development success rates, fewer than 10% of programs that enter the clinic reach approval. Several groups have looked at whether human genetics evidence improves those odds, including an independent analysis published in Nature. They reported that programs with any human genetics evidence supporting the target, based on analysis of common variants, had 2.6-fold higher success rates. Our analysis of the available data yielded similar results, about 2.8-fold. We extended this analysis to programs with rare, large-effect protective genetic evidence, which is only attainable by sequencing exomes or genomes, and found that these programs have about six-fold higher success rates.
This supports our approach of prioritizing targets backed by human genetics, especially rare protective variants, which provide the strongest validation and the greatest probability of success. One major area of focus for the RGC has been large-effect genetics, and these variants are almost always rare, requiring very large sample sizes to uncover them. The line here shows our cumulative samples sequenced over time. As we have scaled our databases over the last decade, we have repeatedly seen that the more rare variants, the larger the effects are on a trait, disease, or phenotype. Increasing scale and diversity allows us to discover more and more incredibly rare, therapeutically relevant gene variants, leading to better drug targets. Our dataset also includes 1 million participants who are not of European ancestry, which helps ensure our discoveries apply to more patients. Highlighted here are three examples. Next slide, please. One of our earliest MASH discoveries was a protective variant in the HSD17B13 gene, carried by about one in three people.
This common variant gave a meaningful, but from today's perspective, modest 16% reduction in the risk of liver disease. Next, please. A few years later, with about 540,000 sequenced samples linked to health records, we found a much rarer protective variant in the CIDEB gene. Only one in 500 people carry it, but the effects are larger, a 43% lower risk of developing liver disease and 22% lower liver fat. We first published this in 2022 and have recently confirmed the findings in a larger dataset of 1 to 2 million samples in the New England Journal of Medicine. Next, please. As our capabilities grow, we find even rarer variants with even larger effect sizes.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
